GE HealthCare director buys 10,000 GEHC shares

GE HealthCare Technologies Inc. director Kevin Lobo reported an open-market purchase of 10,000 shares of common stock at $64.18 per share.

Filing Impact

(High)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

GE HealthCare Technologies Inc. director Kevin Lobo reported an open-market purchase of 10,000 shares of common stock at $64.18 per share. After this transaction, he directly owns a total of 14,363 shares of GE HealthCare common stock.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Lobo Kevin

Role Director

Bought 10,000 shs ($642K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.01 per share	10,000	$64.18	$642K

Holdings After Transaction: Common Stock, par value $0.01 per share — 14,363 shares (Direct)

Key Figures

Shares purchased: 10,000 shares Purchase price: $64.18 per share Shares owned after transaction: 14,363 shares +1 more

4 metrics

Shares purchased 10,000 shares Open-market purchase on 2026-05-22

Purchase price $64.18 per share Open-market purchase of common stock

Shares owned after transaction 14,363 shares Direct holdings following the reported trade

Transaction code P Purchase in open market or private transaction

Key Terms

Common Stock, par value $0.01 per share, open-market purchase, Form 4

3 terms

open-market purchase financial

"transaction_action: open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kevin Lobo report at GEHC?

Kevin Lobo reported an open-market purchase of GE HealthCare Technologies Inc. common stock. He bought 10,000 shares in a single transaction, as disclosed in a Form 4 insider filing for the company.

How many GEHC shares did Kevin Lobo buy and at what price?

Kevin Lobo bought 10,000 shares of GE HealthCare Technologies Inc. common stock. The purchase price was $64.18 per share in an open-market transaction, according to the Form 4 disclosure.

What is Kevin Lobo’s role at GE HealthCare Technologies Inc. (GEHC)?

Kevin Lobo is identified as a director of GE HealthCare Technologies Inc. in the insider filing. The Form 4 notes he is not an officer and not a ten percent owner of the company’s stock.

How many GEHC shares does Kevin Lobo own after this Form 4 transaction?

After the reported purchase, Kevin Lobo directly owns 14,363 shares of GE HealthCare Technologies Inc. common stock. This total includes the newly acquired 10,000 shares from the open-market transaction disclosed.

Was Kevin Lobo’s GEHC trade an open-market purchase or another type?

The Form 4 describes Kevin Lobo’s transaction as an open-market purchase. The transaction code is “P,” and the filing labels it specifically as an open-market purchase of common stock at a stated price per share.

Does the Form 4 show any derivative positions for Kevin Lobo in GEHC?

The insider filing’s derivative summary is empty, indicating no derivative transactions or remaining derivative positions are reported for Kevin Lobo in this particular Form 4 submission for GE HealthCare Technologies Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/26/2026 - 06:44 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lobo Kevin

(Last)

(First)

(Middle)

500 WEST MONROE STREET

(Street)

CHICAGO

ILLINOIS

60661

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GE HealthCare Technologies Inc. [ GEHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.01 per share	05/22/2026		P		10,000	A	$64.18	14,363	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	/s/ Frank R. Jimenez, General Counsel and Corporate Secretary, as attorney-in-fact	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR